PMC:7172841 / 25816-26460
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T177 | 130-134 | Body_part | denotes | hand | http://purl.org/sig/ont/fma/fma9712 |
T178 | 153-161 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
T179 | 208-217 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
T180 | 253-257 | Body_part | denotes | hand | http://purl.org/sig/ont/fma/fma9712 |
T181 | 336-339 | Body_part | denotes | HLA | http://purl.org/sig/ont/fma/fma84795 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T19 | 130-134 | Body_part | denotes | hand | http://purl.obolibrary.org/obo/UBERON_0002398 |
T20 | 253-257 | Body_part | denotes | hand | http://purl.obolibrary.org/obo/UBERON_0002398 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T226 | 93-101 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T227 | 93-97 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T236 | 29-30 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T161 | 230-232 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T163 | 310-312 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T165 | 340-342 | Chemical | denotes | DR | http://purl.obolibrary.org/obo/CHEBI_73445 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T31 | 153-172 | http://purl.obolibrary.org/obo/GO_0001816 | denotes | cytokine production |
T32 | 598-625 | http://purl.obolibrary.org/obo/GO_0050728 | denotes | anti-inflammatory responses |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T186 | 0-354 | Sentence | denotes | In conclusion, we identified a unique signature of immune dysregulation in the patients with SARS-CoV-2, characterized on the one hand by normal or high cytokine production capacity and increased circulating cytokines (especially IL-6) and on the other hand by defects in the lymphoid function associated with IL-6-mediated decrease in HLA-DR expression. |
T187 | 355-644 | Sentence | denotes | These findings support the rationale of launched clinical trials on the efficacy of Anakinra, Sarilumab, Siltuximab, and Tocilizumab (Clinicaltrials.gov NCT04330638, NCT04317092, and NCT04315298 and EudraCT number 2020-001039-29) to elaborate anti-inflammatory responses in these patients. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T92 | 51-71 | Phenotype | denotes | immune dysregulation | http://purl.obolibrary.org/obo/HP_0002958 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T815 | 51-57 | UBERON:0002405;GO:0006955 | denotes | immune |
T816 | 58-71 | GO:0006955 | denotes | dysregulation |
T817 | 93-103 | SP_7 | denotes | SARS-CoV-2 |
T818 | 230-234 | PR:000001393 | denotes | IL-6 |
T819 | 310-314 | PR:000001393 | denotes | IL-6 |
T820 | 336-339 | PR:000029150 | denotes | HLA |
T821 | 343-353 | GO:0010467 | denotes | expression |
T822 | 449-458 | DG_39 | denotes | Sarilumab |
T823 | 476-487 | DG_35 | denotes | Tocilizumab |
T50203 | 39-47 | SP_7 | denotes | ignature |
T29702 | 148-153 | UBERON:0002405;GO:0006955 | denotes | high |
T17561 | 154-167 | GO:0006955 | denotes | ytokine produ |
T90888 | 189-199 | SP_7 | denotes | reased cir |
T69958 | 326-330 | PR:000001393 | denotes | crea |
T56935 | 406-410 | PR:000001393 | denotes | inic |
T72906 | 432-435 | PR:000029150 | denotes | acy |
T21106 | 439-449 | GO:0010467 | denotes | Anakinra, |
T43307 | 546-555 | DG_39 | denotes | 298 and E |
T89983 | 573-584 | DG_35 | denotes | -001039-29) |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1012 | 230-234 | Gene | denotes | IL-6 | Gene:3569 |
1013 | 310-314 | Gene | denotes | IL-6 | Gene:3569 |
1014 | 79-87 | Species | denotes | patients | Tax:9606 |
1015 | 93-103 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1016 | 635-643 | Species | denotes | patients | Tax:9606 |
1017 | 449-458 | Chemical | denotes | Sarilumab | MESH:C000592401 |
1018 | 460-470 | Chemical | denotes | Siltuximab | MESH:C504234 |
1019 | 476-487 | Chemical | denotes | Tocilizumab | MESH:C502936 |